ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$105.04
−1.82%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -71.6%
- Free cash flow
- -24.6%
- Operating cash flow
- -25.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +64.9%
- EPS
- +52.2%
Three-year CAGR
- Revenue
- —
- EBITDA
- -84.8%
- EBIT
- -42.2%
- Net income
- -90.7%
- EPS
- -66.1%
- Free cash flow
- -0.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Dec 1, 2025